Drug combo aims to shrink tumors before melanoma surgery
NCT ID NCT01972347
Summary
This study is testing if giving two targeted drugs (dabrafenib and trametinib) for 12 weeks before surgery can shrink melanoma tumors that have spread to the lymph nodes. It involves 35 adults with a specific genetic mutation (BRAF V600). The main goal is to see if this pre-surgery treatment reduces the amount of cancer tissue and improves surgical and long-term results.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Melanoma Institute Australia
Wollstonecraft, New South Wales, 2065, Australia
Conditions
Explore the condition pages connected to this study.